Drug Trial Radar · NCT07180355
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Oct 22, 2025
Primary completion
Mar 21, 2028
Study completion Feb 29, 2032
Sponsor
- Lead sponsor
- Solid Biosciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.
Conditions
- Friedreich's Ataxia (FA)
Interventions
SGT-212Drug
Adeno-associated virus serotype AAVhu68 containing a codon-optimized complementary DNA (cDNA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)Time frame: Month 12
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
The University of California, Los Angeles (UCLA)
Los Angeles, California · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
The Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.